Publication:
Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma

Simple item page
dc.contributor.authorKAYA, HANDAN
dc.contributor.authorsSahin Ozkan, Hulya; Ugurlu, Mustafa Umit; Yumuk, Perran Fulden; Kaya, Handan
dc.date.accessioned2022-03-12T22:40:40Z
dc.date.available2022-03-12T22:40:40Z
dc.date.issued2020
dc.description.abstractTumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study, CD8, FOXP3, CD163, PD-L1/SP142 and PD-L1/SP263 antibodies were examined in a sample of 51 TNBC cases. Patients who received neoadjuvant therapy were excluded. CD8, FOXP3 and CD163 antibodies were evaluated separately in intratumoral area (ITA) and tumor stroma (TS). PD-L1 status was also examined in tumor cells (TC) and immune cells (IC) using both SP142 and SP263 antibodies. In multivariate Cox regressions, the only antibody that was found to be significantly associated with survival was SP142. SP142-positivity in TC and IC was related to increased overall survival. Higher CD163 expression in ITA and SP263-positivity in IC were associated with younger age. Lymphatic/angioinvasion was more frequent in cases with negative/low CD8 and FOXP3 expressions. Moreover, metastatic axillary lymph node(s) was associated with negative/low FOXP3 expression in TS. CD8, FOXP3, CD163, SP142 and SP263 expressions were positively correlated with each other, except a mild discordance caused by CD163 in ITA. Although PD-L1 status with both SP142 and SP263 antibodies were concordant in the majority of cases, 33.3% and 13.7% of the cases showed SP142-negative/SP263-positive pattern in TC and IC respectively. In conclusion, we suggest that composition, density and localization of the immune cells and the check point molecules are important prognostic parameters in TNBC. Immunohistochemistry can be used as an accessible and less expensive tool to demonstrate TIME.
dc.identifier.doi10.1007/s12253-020-00874-4
dc.identifier.eissn1532-2807
dc.identifier.issn1219-4956
dc.identifier.pubmed32681436
dc.identifier.urihttps://hdl.handle.net/11424/236001
dc.identifier.wosWOS:000549706100001
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofPATHOLOGY & ONCOLOGY RESEARCH
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTriple negative breast cancer
dc.subjectTumor infiltrating lymphocytes
dc.subjectTumor associated macrophages
dc.subjectPD-L1
dc.subjectFork head box protein 3
dc.subjectImmunohistochemistry
dc.subjectTUMOR-INFILTRATING LYMPHOCYTES
dc.subjectFOXP3 EXPRESSION
dc.subjectPOOR-PROGNOSIS
dc.subjectT-CELLS
dc.subjectCLINICAL-SIGNIFICANCE
dc.subjectPD-L1 EXPRESSION
dc.subjectCANCER SUBTYPES
dc.subjectMACROPHAGES
dc.subjectIDENTIFICATION
dc.subjectSURVIVAL
dc.titlePrognostic Role of Immune Markers in Triple Negative Breast Carcinoma
dc.typearticle
dspace.entity.typePublication
local.avesis.id172e84d5-9383-4607-837b-3870fede2255
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages13
local.journal.quartileQ2
oaire.citation.endPage2745
oaire.citation.issue4
oaire.citation.startPage2733
oaire.citation.titlePATHOLOGY & ONCOLOGY RESEARCH
oaire.citation.volume26
relation.isAuthorOfPublication0bf301ff-2544-4a5e-b38b-b43084d6c255
relation.isAuthorOfPublication.latestForDiscovery0bf301ff-2544-4a5e-b38b-b43084d6c255

Files

Collections

Research Outputs